Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Downgrades Fastenal to Neutral, Announces $48 Price Target

Baird Downgrades Fastenal to Neutral, Announces $48 Price Target

Baird analyst David Manthey downgrades Fastenal (NASDAQ:FAST) from Outperform to Neutral and announces $48 price target.

byBenzinga Newsdesk

July 14, 2022

1 minute read

Baird analyst David Manthey downgrades Fastenal (NASDAQ:FAST) from Outperform to Neutral and announces $48 price target.

Analyst Ratings

The Latest Analyst Ratings for SpringWorks Therapeutics

By Benzinga Insights

June 6, 5:00 PM

Over the past 3 months, 4 analysts have published their opinion on SpringWorks Therapeutics (NASDAQ:SWTX) stock. These analysts…

SWTX

Analyst Ratings

Expert Ratings for Earthstone Energy

By Benzinga Insights

June 16, 1:00 PM

Within the last quarter, Earthstone Energy (NYSE:ESTE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

ESTE

Guardion Health Sciences Q2 EPS $(0.03) Up From $(0.10) YoY, Sales $3.28M Up From $1.22M YoY

By Bill Haddad

August 11, 8:20 AM

Guardion Health Sciences (NASDAQ:GHSI) reported quarterly losses of $(0.03) per share. This is a 70 percent increase over losses of $(0.10) per share from the same period last year. The company reported $3.28 million in

GHSI

Analyst Ratings

Expert Ratings for Globus Medical

By Benzinga Insights

November 8, 2:00 PM

Globus Medical (NYSE:GMED) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

GMED

Baird Downgrades Fastenal to Neutral, Announces $48 Price Target

Related Posts

The Latest Analyst Ratings for SpringWorks Therapeutics

Expert Ratings for Earthstone Energy

Guardion Health Sciences Q2 EPS $(0.03) Up From $(0.10) YoY, Sales $3.28M Up From $1.22M YoY

Expert Ratings for Globus Medical